The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global apoptosis assay market is expected to exhibit a CAGR of 8.87% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Apoptosis assays are used by researchers to detect biochemical and cellular events associated with programmed cell death. They provide in-depth insights into cell death mechanisms, small molecule and biological drugs, and functions of the immune system at the molecular level. Presently, a significant increase in the incidences of cancer has escalated the adoption of apoptosis assays to understand the effects of gene and chemotherapy drugs in both in vitro and in vivo conditions. Moreover, as these assays determine the sensitivity of given cancer cells to a specific drug, they help in developing a therapeutic strategy accordingly.
Apoptosis or programmed cell death mechanism plays a crucial role in the onset and progression of several chronic conditions. The widespread adoption of clinical cytoprotective and cytotoxic agents in treating ischemic diseases, cancer and neurodegenerative diseases represents one of the leading factors increasing the demand for apoptosis assays to discover novel drugs. Moreover, real-time and live-cell assays are gaining traction with multiple other methods to monitor apoptotic events over time. The rising focus on extensive research on therapeutic drugs by governing agencies of numerous countries is also contributing to the market growth. Furthermore, numerous pharmaceutical manufacturers are developing economical and innovative assay kits, reagents, and instruments, which is influencing the market growth. Apart from this, researchers have found that the coronavirus disease (COVID-19) infection activates caspase-8 and triggers cell apoptosis and inflammatory cytokine processing in the lung cells. This is anticipated to expand the applications of apoptosis in the development of therapeutic strategies to treat viral infection.
IMARC Group provides an analysis of the key trends in each sub-segment of the global apoptosis assay market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, technique, assay type and end use .
Breakup by Product:
Breakup by Technique:
Breakup by Assay Type:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam plc, Agilent Technologies Inc., Becton Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Merck KGaA, PerkinElmer Inc., Promega Corporation, Sartorius Aktiengesellschaft, Takara Bio Inc. and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Technique, Assay Type, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abcam plc, Agilent Technologies Inc., Becton Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Merck KGaA, PerkinElmer Inc., Promega Corporation, Sartorius Aktiengesellschaft, Takara Bio Inc. and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at